ArticleScientific reports2025
Purification and characterization of an antimicrobial compound against drug-resistant MRSA and VRE produced by Streptomyces levis strain HFM-2.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
Due to high resistance to medicines, multidrug-resistant (MDR) bacterial pathogens, particularly MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant enterococci), are a significant public health concern for treating nosocomial infections. Researchers are developing novel compounds responding to the global rise in MDR infections. This study aimed to extract, purify, and characterize bioactive metabolites from Streptomyces levis strain HFM-2, a human gut isolate, exhibiting strong antimicrobial activity against several MDR pathogenic bacteria and fungal phytopathogens. Ethyl acetate extract of S. levis strain HFM-2 was purified using silica-gel column chromatography and reverse-phase high-performance liquid chromatography. Structure elucidation of the purified antimicrobial compound was done by performing detailed analyses including MS, IR, and NMR. The bacteriostatic activity of the compound revealed interesting values against broad-spectrum MDR pathogens. The bacterial cell destruction was recorded through SEM and fluorescence microscopy analyses. HFM-2P is displayed to be non-mutagenic and non-cytotoxic to the normal cell line. However, dose-dependent cytotoxicity was observed against the HeLa cancer cell line and exhibited antimutagenic activity against Salmonella Typhimurium strains (TA98 and TA100). This study is the first to report antiproliferative, DNA protective potential, antimutagenic properties, and antimicrobial activity of a 2,6-disubstituted chromone derivative isolated from S. levis strain HFM-2 against drug-resistant MRSA, VRE, and fungal phytopathogens. Therefore, this essential compound could be a candidate for future research in the pharmaceutical and agricultural sectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.